JPS5853760A - Screening of antitumor polysaccharide - Google Patents

Screening of antitumor polysaccharide

Info

Publication number
JPS5853760A
JPS5853760A JP15264581A JP15264581A JPS5853760A JP S5853760 A JPS5853760 A JP S5853760A JP 15264581 A JP15264581 A JP 15264581A JP 15264581 A JP15264581 A JP 15264581A JP S5853760 A JPS5853760 A JP S5853760A
Authority
JP
Japan
Prior art keywords
polysaccharide
solution
those obtained
screening
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP15264581A
Other languages
Japanese (ja)
Other versions
JPH0151785B2 (en
Inventor
Junji Kakinuma
垣沼 淳司
Tsuneo Asano
浅野 常夫
Koichiro Otsu
大津 紘一郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP15264581A priority Critical patent/JPS5853760A/en
Publication of JPS5853760A publication Critical patent/JPS5853760A/en
Publication of JPH0151785B2 publication Critical patent/JPH0151785B2/ja
Granted legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

PURPOSE:To achieve the screening of an antitumor polysaccharide simply and quickly, by bringing a diluted polysaccharide solution not containing endotoxin into contact with a hemocyte extract of a horseshoe crab. CONSTITUTION:This screening of a polysaccharide having an antitumor effect is characterized by selection of a polysaccharide indicating positivity in a Limulus test by bringing a diluted polysaccharide solution not substantially containing endotoxin into contact with a hemocyte extract of a horseshoe crab. Applicable polysaccharide includes those obtained from animals, higher plants and lichen, those obtained from bodies and culture solutions of mildew, bacteria and yeast and additionally, those obtained by oxidation, reduction or hydrolysis of these polysaccharides and those obtained by the hydroxyethylation and carboxymethylation thereof. The measurement of the positivity in the Limulus test is done by determining the extent of gelation of the hemocyte extract of the horseshoe crab or the activity of a coagulated enzyme.

Description

【発明の詳細な説明】 本発明はカブトガニ0*球抽出液を月いて抗腫瘍多糖O
スクリーニングを行なう方法に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention uses horseshoe crab O* bulb extract to produce antitumor polysaccharide O.
Relates to a method of screening.

抗腫瘍多糖は宿主の抵抗性を増強させて腫瘍の成長を抑
制するいわゆる免疫賦活剤に含まれるものであり、種々
O化学療法剤にくらぺて紘るかに副作用が弱いとともあ
って、避年そO有用性が益々注目されつつある。とれも
O抗腫瘍多糖は自然界に広く分布してお)、えとえばV
イlケから紘レンチナンが、夜苓からはパ艦マフンが、
カヲラタケカラはクレスチンが、スエと一タケからはV
ゾツイフンが、酵母からはザイ碌ザンが、麦わらかbは
ヘミセルロースが、地衣類からはGK−3が取得されて
いる。これらの中にはすでに癌の免疫療法剤として高く
評価されてiるものもあり、tえ現在制癌剤としての開
発が進行中040もあるが、さらに有効な抗腫瘍多糖を
見いだす丸めO研究(広く活発に行なわれている。
Antitumor polysaccharides are included in so-called immunostimulants that increase host resistance and suppress tumor growth, and they have far less side effects than various chemotherapy drugs. Its usefulness in avoiding the new year is attracting more and more attention. Toremo O anti-tumor polysaccharides are widely distributed in nature), for example V
Hiro Lentinan from Iruke, Pakan Mafun from Yarei,
Kawora Takekara is Krestin, Sue and Ichitake are V.
Zotsuifun has been obtained from yeast, Zairokuzan has been obtained from yeast, hemicellulose has been obtained from wheat straw, and GK-3 has been obtained from lichen. Some of these have already been highly evaluated as cancer immunotherapeutic agents, and some are currently under development as anticancer agents, but round-O research to find even more effective antitumor polysaccharides (widely It is actively carried out.

これらO多糖O抗鳳瘍効果の測定は、通常、マ?XK移
植し九ザρコーマ180.エールリッヒカルtノーマ、
CCMアデノカルチノーマなどに賞する多糖O威畏抑制
効果を調べるととによって行なわれているが、との方法
は多ぐO実験動物と特at技術を必要とし、一方で効果
O判定に1ケ月%0II−期閤を要するので莫大な経費
と多くの労力が要求される。
The measurement of the anti-inflammatory effect of these O polysaccharides is usually carried out using Ma? XK ported and nine ρ coma 180. Ehrlich Calt Norma,
The inhibitory effect of polysaccharides on CCM adenocarcinoma, etc., has been investigated by and, but this method requires a large number of experimental animals and special AT techniques, and on the other hand, it takes one month to determine the effectiveness. %0II- Since it requires a lot of time, it requires a huge amount of expense and a lot of effort.

一方、λILシ11(klL Johns 1lopk
i鶴Io町ら98325 (111g6))によ)カプ
トtr−ojk液が鈑黴量O内毒素の存在下でゲル化す
ることが見出さ決として汎用されるようKなった1通常
、リムρステス)による内毒素の検出には内毒素によ)
生じたゲルの固さを試験管を傾けて南限的に判定する方
法と、内毒素の存在下に不活性前駆体から活性化されこ
Oグ〃廖威に関与する凝IiI酵素のアミダーゼ活性を
合成基質を用いて測定する方法とがある。
On the other hand, λIL Johns 1lopk
It was discovered by Tsuru Iocho et al. 98325 (111g6)) that the capto-tr-ojk solution gelled in the presence of endotoxin, and it became widely used. ) to detect endotoxins (by endotoxins)
The stiffness of the resulting gel can be determined by tilting the test tube, and the amidase activity of the coagulation III enzyme, which is activated from an inactive precursor in the presence of endotoxin and is involved in Ogglutination, has been investigated. There is a method of measuring using a synthetic substrate.

本発明者らは内毒素の混入していない各種抗腫瘍多糖標
品がカブトガニ抽出液を強くゲル化することをI+−だ
し、種々検討を加え九結果、こ0グル化が抗腫瘍多糖の
特定濃度範囲内において0み起ζ)、このIIm!以外
の濃度では起ζら1%/%ことおよびこのような特異な
ゲル化パターンが抗腫瘍作用を有する多糖K11つて見
られることを認め、鋭意検討の結果本発明を完成するに
至り九。
The present inventors found that various anti-tumor polysaccharide preparations that are not contaminated with endotoxins strongly gelled horseshoe crab extracts, and after conducting various studies, they found that this 0-gluation is the identification of anti-tumor polysaccharides. 0 occurrence ζ within the concentration range), this IIm! It was recognized that at concentrations other than 1%/%, and that such a unique gelation pattern was observed in polysaccharide K11, which has an antitumor effect, the present invention was completed as a result of intensive studies.

本発明は、カブトガ=の血球抽出物Kl!質上エンドト
キVンを含まない多糖希薄液を接触させ、リムヤステス
ト陽性を示す多糖を選択することを特徴とする抗腫瘍作
用を有する多糖のスタリーエ地衣類から得られる多糖、
カビ、細1および酵母の菌体および培養液から得られる
多糖、さらにはこれら多糖を酸化、還元または加水分解
して得られる多糖中とトーキVエチル化、カルボキVメ
チル化録はにドロ等Vエチル化して得られる多tが含ま
れる。しかもこれら多糖は水に対すゐ溶解性の%/%か
んKかかわらず適、用することができる。
The present invention provides a hemocyte extract of Kabutoga Kl! A polysaccharide obtained from Starier lichen, a polysaccharide having an antitumor effect, characterized by contacting with a polysaccharide dilute solution that does not contain endotoxin, and selecting a polysaccharide that shows a positive Rimuyas test.
Polysaccharides obtained from the cells and culture fluids of molds, microorganisms, and yeasts, as well as polysaccharides obtained by oxidizing, reducing, or hydrolyzing these polysaccharides, as well as polysaccharides obtained by oxidation, reduction, or hydrolysis, ethylation, carboxymethylation, etc. It includes t-t obtained by ethylation. Moreover, these polysaccharides can be applied and used regardless of their solubility in water.

多糖希薄液の多糖0濃度唸、多糖によって異な為が、通
常は約2 X 10−”11/dFJhb 2 X 1
0−’q/dO濃度O%のを準備すればよい。多糖希薄
液としては、多糖が水に溶解するものである場舎には水
溶液を、多糖が水に溶解しないものである場舎には、■
濁液を用iればよ−。
The zero concentration of polysaccharide in the diluted polysaccharide solution varies depending on the polysaccharide, but it is usually about 2 x 10-"11/dFJhb 2 x 1
0-'q/dO concentration 0% may be prepared. As a polysaccharide dilute solution, an aqueous solution is used in cases where the polysaccharide is soluble in water, and an aqueous solution is used in cases where the polysaccharide is not dissolved in water.
Just use a cloudy solution.

本発明で用いる多糖希薄液は、夾貿上工ンドトキVンを
含11いもOを用iる必要がある。!J買上エンド)(
Fンを食ま′&−とは、工ンドトキVン含量が被検多糖
試料轟た311 ppm以下、さらに好ましくは0.l
ppm坂下で以下ことをいう。
The polysaccharide dilute solution used in the present invention needs to contain 110% of foreign materials. ! J purchase end) (
"Fun" means that the polysaccharide sample to be tested has a polysaccharide content of 311 ppm or less, more preferably 0. l
ppm Sakashita refers to the following.

実質上エンド)キレンを含まないようkするに#i、多
糖試料を2MI/lとなるようKO,1夏水酸化ナトリ
クム溶液に溶解、まえは懸濁させ、4℃で一夜放置して
脱エンドトキVン処理を施ζせばよい。
To ensure that the polysaccharide sample is substantially free of endotoxins, dissolve the polysaccharide sample in a sodium hydroxide solution of 2 MI/l, suspend it, and leave it at 4°C overnight to remove endotoxins. What is necessary is to perform a V-coating process.

リムνレステストにシけるカブトガニの血球抽出物を提
供するカブ)ガニとしては、分類学上カブ)に類(1諌
虹鎌JL)K属するものであれば−ずれも使用すること
ができ、例えば日本産の4 trld@ntatus 
、米国産OLim1山辿polyp)leans e東
南アジア産のCarolnoaoor 1txs匹1囚
■4匹μ議、艷眸Vハ懸〔覆堕、!畦と粉μis tr
id@ntat■などが使用できる。更に血球抽出液と
してはカブ)f=から採血して得九血球を低張下に処理
して得られる抽出液を直接使用して4よく、また、市販
品たとえばプレゲル(帝国臓器製薬株式会社製)、ビ田
チル(Pyrot・11)〔ムamooiates o
f Cape Cod Xna、 (米国)製〕、イー
−)キセイ) (1−Tomt*)(81μChemi
oal Company (米国)製〕、ピロジエン)
(Pyrog@nt ) (Malllnokrodt
、InaI(米国)製〕、ピ田テス) (Pyrot軸
t ) (Difoo Iabe−ratories 
(米国) jll ) 、 Miorobiolog1
calAsscxriat@s (米国)腰のリムルス
・アメーボtイト・ツィゼイト(LAL)などを使用し
てもよく、一般的には市販のエンドトキVン検出用の標
品を溶解して使用するのが簡便である。
As the horseshoe crab that provides the hemocyte extract of the horseshoe crab that can be used in the rim ν-less test, any crab that belongs to the taxonomic classification (1. For example, 4 trld@ntatus from Japan
, American OLim 1 mountain trail polyp) leans e Carolnoaoor from Southeast Asia 1 txs 1 prisoner ■ 4 μ discussion, eyes V ha hanging [overturned,! Ridge and powder μis tr
id@ntat■ etc. can be used. Furthermore, as a blood cell extract, an extract obtained by collecting blood from turnips and treating the blood cells obtained under hypotonic conditions can be used directly. ), Pyrot 11
f Cape Cod
oal Company (USA)], Pyrodiene)
(Pyrog@nt) (Mallnokrodt)
, InaI (USA)], Pyrot axis) (Difoo Iabe-ratories)
(USA) jll), Miorobiolog1
calAsscxriat@s (USA) Limulus amoebot zyzeit (LAL) may also be used, but it is generally convenient to dissolve and use a commercially available preparation for endotoxin detection. be.

リムルステスト陽性を測定するには、カブトガニ血球抽
出液がゲル化する程度を測定するか、凝固酵素oH性を
測定すればよい。
A positive Limulus test can be determined by measuring the degree of gelatinization of the horseshoe crab blood cell extract or by measuring the OH property of a coagulating enzyme.

本発明の方法において、抗腫瘍多糖とカブトガニ血球抽
出液とを夏応畜せ九際のゲル化の程度を測定するには、
(1)ゲfi/の硬さを南限的に判定する方法、(8)
ゲル化し九蛋白量を通常0蛋白定量法例えばLawry
法などで測定する方法、(S)ゲル化に伴う濁度O増加
を比濁計で測定する方法、(4)125工で1織しえ凝
a蛋白(:Iアギューゲン)のゲル内へO取)込みを測
定する方法のいずれを用いても酸化ナトリウムに溶解ま
たは懸濁し、4℃で一夜放置しえのち、エンド)キレン
を食まない0.4さらに希釈して種々の濃度の多糖希薄
液を調製する* (g)*ブトガニ直球抽出物を局方注
射用蒸留水o、IIItKjll解する。(3)各種濃
度の多糖希薄液0.1dをカブ)ガニ血球抽出物含有液
0.1mK添加し、ゆるやかに混合する。(4)パフフ
ィルムで反応液O入つ九審器を冑封し九のち、37℃で
1時間静置し、さらに室温で5分間静置する。(5)客
器を45”K傾斜させ、ゲル化の程度を次のように南限
的に判定する。
In the method of the present invention, in order to measure the degree of gelation when the anti-tumor polysaccharide and horseshoe crab blood cell extract are combined in summer,
(1) Method of determining the hardness of Gefi/ in a southern limit, (8)
After gelation, the amount of protein is usually determined using a protein assay method such as Lawry.
(S) A method of measuring the increase in turbidity O due to gelation using a nephelometer. Regardless of the method used to measure uptake, the polysaccharide is dissolved or suspended in sodium oxide, left overnight at 4°C, and then further diluted to obtain polysaccharide dilutions of various concentrations. Preparing the solution * (g) * Dissolve the Boletus crab extract in distilled water for pharmacopoeial injections. (3) Add 0.1 d of polysaccharide dilute solution of various concentrations and 0.1 mK of turnip/crab blood cell extract-containing solution and mix gently. (4) Seal the container containing the reaction solution O with puff film, and then leave it at 37°C for 1 hour, and then leave it at room temperature for 5 minutes. (5) Tilt the container by 45"K and judge the degree of gelation from the southern limit as follows.

+:固いゲルを廖成し客器を傾けてもグルO廖が崩れな
い。
+: Forms a solid gel and the gel does not collapse even if the container is tilted.

+;ゲルを形成しているが客器を傾けると塊)の11動
く。
+: Forms a gel, but when the container is tilted, the lumps) move.

±:柔か一半流動性のゲルを形成し、頷けると流れる。±: Forms a soft or semi-fluid gel, and flows smoothly.

m:流状の11でほとんど変化がない。m: Fluid 11 with almost no change.

リムルステスト陽性を示すと杜、この肉隈的判室法にお
いて、士以上のゲル化を示すことである。
A positive limulus test indicates a degree of gelatinization above that of a professional in this Nikkuma courtroom law.

tえ、抗腫瘍多糖Oカブトガニ血球抽出液のゲj&[酸
部と凝固酵素前駆体の凝固酵素への活性化とは密接KJ
I関するので、ゲル化−i測定する代わ)に夏応液申に
生成している凝固酵素の活性を直接測定してもよい。こ
O凝固酵素の基質としてはペプチドにノCチーニトロア
ニリン(plA)を納金させた!11(le−Glu−
Gly−ムrg−pHム、Bm−マ4l−Gly−ムr
g−p璽ム、  1loo−Leu−Gly−ムrg−
plム、  Boo−get(OBg)−Gly−ムr
g−p璽ム、  Boo−マ&1−L@u−Gly−ム
rg−p11ムおよびl1oo−マal−4@r−G1
7一ムrg−plAなどが使用できる。またこれらの基
質のアミノ酸配列を残し九tま発色団のplAを!1党
性Ohる1−アミノ−4−メチルタマリン(ム菖C)に
置換し九ペプナドーMCムを基質とし   ゛て使用し
てもよ−、上瀘0ペプチドplムを基質としえ時には遊
離して(るp夏ム量を405 nNにおける吸光度で測
定してもよ<、1九夏応液にジアゾ化試薬を加えてpl
Aを赤色アゾ色素に変えて測定してもよい、ペプチド−
MCムを基質とし九時には同様に生威すゐムMCO賛光
を測定すればよい0例えば、発色性合成基質を用いゐ工
ンドトキV’/40定量法〔ヘモスIVス(ム軸oat
a−社−) 7 、183(1978) )を応用した
際OA体的操作法社次O過)である、(1)カブ)ガニ
血球抽出物を0.4M)’jヌ・塩酸−0,04MMg
C1g緩衝液(pl g、O)O,SdK溶解する。徊
)発色性合成基質01りである1loo−Leu−Ql
y−ムrg−pHム−HC1を1.84/srとなるよ
うに注射用蒸留水に溶解する。(3)前述の種々の濃度
の多糖希薄液0.05mにカブトガニ血球抽出物含有液
0.025dThよび会成基質溶液0.0251を添加
し、3γ℃で30分間夏広させる。(4)反応後12.
5XO酢酸9.4agを添加して反応を停止させ、40
5 all K>ける吸光度(ム40.)を測定する。
te, Anti-tumor polysaccharide O horseshoe crab hemocyte extract gel & [The acid part and the activation of coagulation enzyme precursor to coagulation enzyme are closely related.
Regarding I, instead of measuring gelation-i), the activity of the coagulating enzyme produced in the summer liquid may be directly measured. As a substrate for this coagulating enzyme, the peptide was made to use NOC nitroaniline (plA)! 11(le-Glu-
Gly-mrg-pHm, Bm-ma4l-Gly-mr
g-p seal, 1loo-Leu-Gly-mrg-
plm, Boo-get(OBg)-Gly-mr
g-p mark, Boo-ma&1-L@u-Gly-mrg-p11m and l1oo-maal-4@r-G1
71 mu rg-plA etc. can be used. We also leave the amino acid sequences of these substrates and the chromophore plA! It can also be used as a substrate by substituting 1-amino-4-methyltamarin (Musou C) with one-party peptide P1 as a substrate, and sometimes using free peptide Plum as a substrate ( The amount of P summer can be measured by the absorbance at 405 nN.
The peptide may be measured by replacing A with a red azo dye.
For example, using a chromogenic synthetic substrate and measuring the MCO concentration using MC as a substrate, the MCO concentration can be measured in the same manner.
7, 183 (1978)), (1) turnip) crab blood cell extract was added to 0.4M)'jnu hydrochloric acid-0. ,04MMg
Dissolve C1g buffer (pl g, O)O, SdK.徊) 1loo-Leu-Ql, a chromogenic synthetic substrate 01
y-murg-pHmu-HC1 is dissolved in distilled water for injection to a concentration of 1.84/sr. (3) Add 0.025 dTh of the horseshoe crab hemocyte extract-containing solution and 0.0251 ml of the synthetic substrate solution to 0.05 ml of the diluted polysaccharide solutions of various concentrations described above, and incubate at 3γ°C for 30 minutes. (4) After reaction 12.
The reaction was stopped by adding 9.4 ag of 5XO acetic acid,
5 Measure the absorbance (mu 40.) of all K>.

この方法において、リムルステス)陽性を示すとは、ム
405が約O,OS以上の値を示すことである。
In this method, showing positive Limulstes means showing a value of Mu405 of about O,OS or more.

上記KThいて、アミノ酸、ペプチド、保護基について
の略号は、IuPムC−(tie CComm1gm1
o O!11Siologloal Iomeuola
tur*による略号番るいは当該公費における慣用略号
に基づくものであ〉、そ0例を次に挙ける。まえ、アミ
ノ酸などに関し光学異性体がTo)うる場合は、特に明
示しなければL体を示す%Oとする。
In the above KTh, the abbreviations for amino acids, peptides, and protecting groups are IuPmuC-(tie CComm1gm1
O O! 11Siologloal Iomeuola
It is based on the abbreviation number tur* or the abbreviation commonly used in the public funds concerned. Examples of these are listed below. For amino acids, etc., when optical isomers exist (To), unless otherwise specified, %O indicates the L-isomer.

11・ : イソ費イVン Gin  :  グルタミン酸 oxy  :  グサVン ムrg二  アルギニl マ&1 : パダン 1a@u  :  WイVン 3・r ; セ亨ン 1z:  ペンy声 Boo  :  ターV’r9−1トキV力〃ボエ)L
/ 7しこのようにして、抗腫瘍作用を有すゐ多糖社す
ム會ステスジにおいて陽性を示すので、被検試料である
多糖Oうち抗腫瘍作用を有するtのをスタプーエンダす
ることができる。これに対しア藏ロース、アミVペクチ
ン、デキスFツン、ツ覧ナリン、イメツンなどO抗腫瘍
活性を示さ1i多糖およびVクリホスツアミド(アルi
IPρ化剤)、フ声オロウヲVル(代謝拮抗剤)、ビン
クリスチン(植物性被分列毒剤)、プレオマイVン(抗
癌抗性物質)&どの非多糖抗癌剤は10−7〜1o−1
q/ばでゲル化能擬固酵素前駆体活性化能のいずれをも
示さない。
11. : Iso cost i Vn Gin : Glutamic acid oxy : Gusa V nmu rg2 arginyl ma&1 : Padan 1a@u : WiVn3・r; Sehen 1z: Peny voice Boo : Tar V'r9 -1 Toki V force〃Boe)L
7. In this way, since it shows a positive result in the polysaccharide test that has an antitumor effect, it is possible to eliminate the polysaccharide that has an antitumor effect out of the polysaccharide O that is the test sample. On the other hand, 1i polysaccharide and V-clifostamide (ali
10-7 to 1o-1
q/b shows neither gelation ability nor quasi-solid enzyme precursor activation ability.

本発明の方法ではカブトガニの血球抽出物種晶を用いて
試験管内反応を実施すればよいので、通常の突験室にお
いて特殊な技術を用いずに、簡単に、短時間で抗腫瘍多
糖のスタν−二ングを行なうことができる。また本方法
は爽験動物を用いるスタリー二ングにくらべ動物の購入
、飼育に要する美大な経費と多くの労力を節約すること
ができる上、精度のよい結果を得ることができる。 ′
以下に実施例によル本発明O方法をよ)詳細に説明する
が、本発明はこれによって限定されるものではない。
In the method of the present invention, in vitro reactions can be carried out using horseshoe crab hemocyte extract seed crystals, so antitumor polysaccharide can be easily and quickly produced in a normal laboratory without using special techniques. - Able to carry out two operations. In addition, this method can save a great deal of expense and labor required for purchasing and breeding animals, and can provide highly accurate results, compared to starlining using experimental animals. ′
The method of the present invention will be explained in detail below using Examples, but the present invention is not limited thereto.

なお、本発明O方法を実施するに際し、オプトガニム球
抽出液と接触する器具、試薬、II剤などを全てあらか
じめ滅菌し九上脱エンド)キV:/l&瑠を行なう必要
があるとと紘嘗うまでもない。
In addition, when carrying out method O of the present invention, it is necessary to sterilize all instruments, reagents, II agents, etc. that will come into contact with the optoganilum bulb extract in advance, and to carry out the de-endolysis in Kugami). It's no good.

具体的には、ガフス器具は、例えば先ず中性洗剤1次い
で水道水、イオン交換水で充分洗浄し、最後に工ンドト
キVンを含まない滅菌蒸留水で洗浄して、180℃で3
時間、まえは250℃で30分公聴熱滅菌する。ま良溶
剤としての局方注射用蒸留水1局方生理食塩液はそのま
ま使用するととができる。
Specifically, for example, the gaff device is first thoroughly washed with a neutral detergent, then tap water, and ion-exchanged water, and finally washed with sterile distilled water that does not contain chemicals, and then heated at 180°C for 3 days.
Heat sterilize at 250°C for 30 minutes. Pharmacopoeial distilled water for injection as a good solvent 1 Pharmacopoeia physiological saline can be used as is.

実施例1 グρカy (P 8 ) (Cancer Rea 3
8.379(1978)、特会昭48−32673.英
国特許第1352938号、特開昭53−66442)
を2WjI/mtとなるようKO01夏1aO1に溶解
し、−夜放置し丸、0.4M−)1スー塩酸−〇−04
MMgC1g緩胃液(pH8,0)で10倍に希釈した
のち、局方生理食塩水でさらに希釈して種々O濃度oP
es液を調製しえ。
Example 1 guρky (P 8 ) (Cancer Rea 3
8.379 (1978), special meeting 1973-32673. British Patent No. 1352938, Japanese Patent Application Publication No. 53-66442)
Dissolve in KO01 Summer 1aO1 to give 2WjI/mt, leave it overnight, 0.4M-)1S-HCl-04
After diluting 10 times with 1 g of MMgC loose gastric juice (pH 8,0), further diluting with pharmacopoeia saline to obtain various O concentrations.
Prepare ES liquid.

w)、日本産カブ)t=0血球抽出液を含むデレゲρ(
豐■臓器製薬株式会社製 生化学工業販売)のアンプル
内容物を0.3dの上記0.4M)シスー樵酸−0,0
4MMgC1g 緩衝液(pH8,0)K溶解し九(血
球抽出物含有液)。
w), Japanese turnip) Derege ρ containing t=0 blood cell extract (
Add 0.3 d of the contents of the ampule of 0.3 d of the above 0.4 M) cis-wood citric acid-0,0
Dissolved in 4MMgClg buffer (pH 8,0) (solution containing blood cell extract).

ハ)、合成基質11oo−Leu−Gly−ムrg−p
Hム−HClを1.61RI/dとなるように注射用蒸
留水に溶解した。
c), synthetic substrate 11oo-Leu-Gly-mrg-p
HCl was dissolved in distilled water for injection to a concentration of 1.61 RI/d.

;)、イ)で調製し九各種濃度のps溶液O,OSd、
血球抽出物含有液0.025sfおよび合成基質溶液0
.0255gからなる反応液0.1dを滅菌試験管中、
37℃で30分間反応させた。夏応後12.5%の酢酸
0.4dを添加して反応を停止させ、405nmにシけ
る吸光度(ム4o5)を測定して表10結果を得た。
;), ps solutions of nine various concentrations prepared in a), O, OSd,
Blood cell extract containing solution 0.025sf and synthetic substrate solution 0
.. 0.1 d of the reaction solution consisting of 0.0255 g was placed in a sterile test tube.
The reaction was carried out at 37°C for 30 minutes. After the reaction, 0.4 d of 12.5% acetic acid was added to stop the reaction, and the absorbance at 405 nm (mu4o5) was measured to give the results in Table 10.

表1 ps濃度Cl1l/d)  10−710″310−’
 10−’ 10−’ 10−” 10−1ム4o5 
   QDOCLOI Q10 QJII  (L91
  G330D3表IK示tlK、P8はIO”−’>
!び10−’W/dで強い凝固酵素前駆体活性化能を示
した。
Table 1 ps concentration Cl1l/d) 10-710''310-'
10-'10-'10-" 10-1mu4o5
QDOCLOI Q10 QJII (L91
G330D3 table IK shown tlK, P8 is IO"-'>
! It showed a strong coagulation enzyme precursor activation ability at 10-'W/d.

実施例λ ィχPBをiIルボキVメチル化して得られる抗腫瘍性
1IIll&/ボキVメチルβ−1,3−グルカン(C
M P 8 ) (IuroPJ、 Canoer 1
5.211(1979)。
Example λ - Anti-tumor 1IIll&/bokiV methyl β-1,3-glucan (C
M P 8 ) (IuroPJ, Canoer 1
5.211 (1979).

特開昭53−66442)を21e/dとなるようKO
,1璽夏aoIIに溶解し、−夜放置し九のち、実施例
1と同様の方法で希釈して種々の濃度のCMP8溶液を
調製しえ。
KO'd JP-A-53-66442) to become 21e/d.
, 1 in CMP8 aoII, left overnight, and then diluted in the same manner as in Example 1 to prepare CMP8 solutions of various concentrations.

す)、デレゲ〜のアンプル内容物を注射用蒸留水0.1
sfK*解した。
), dilute the contents of the ampoule with distilled water for injection at 0.1
I understood sfK*.

ハχイ)で調製し九各種濃度のCMP8溶液0゜1dを
a)のプレゲルアンプpに添加し、ゆるやかに温合した
0.1 d of the CMP8 solution prepared in step (c) and various concentrations was added to the pregel amplifier p in a) and gently warmed.

二)、パラフイ声五でアンプルを密封し九〇4b、37
℃で1時間静置し、さらに室温でS分間静置しえ。
2) Seal the ampoule with a paraphrase 904b, 37
Let stand at ℃ for 1 hour and then at room temperature for S minutes.

ホχアンプルを45°に傾斜させ、ゲル化の程度を判定
し丸。
Tilt the ampoule at 45° and judge the degree of gelation.

4+:固いゲルを形成し賽器を傾けてもゲルOy#が崩
れない。
4+: A hard gel is formed and the gel Oy# does not collapse even if the bowl is tilted.

+ニゲρを形成しているがアンプルを傾けると塊)のま
ま動く。
+Nigeρ is formed, but when the ampoule is tilted, it moves as a lump).

±:柔かい半流動性のゲルを形成し、傾けると流れる。±: Forms a soft semi-fluid gel and flows when tilted.

m:流状のままではとんど変化がな−。m: There is almost no change in the fluid state.

表2 ゲル強度    −±  ++  廿  +  −−表
2に示すj5K、CMFgは10−’>!び10−’W
II/Idで強いゲル形成能を示しえ。
Table 2 Gel strength -± ++ 廿 + ---j5K and CMFg shown in Table 2 are 10-'>! bi10-'W
Shows strong gel-forming ability with II/Id.

実施例3 イχアメリカ産声プトガ=0血球抽出液を含むリムルス
テス)ツー−(As5sooiat@s of Cap
e CodInn、製、和光純薬工業株式余社販売)O
1検体測定分を0.3dOO,4M)IX−jj[酸−
o、。
Example 3 As5sooiat@s of Cap
e Manufactured by CodInn, sold by Wako Pure Chemical Industries, Ltd.) O
One sample measurement amount was 0.3 dOO, 4 M) IX-jj [acid-
o.

4MMgC]41111液(pH8,0)K溶解しぇ(
血球紬出怜會有液)。
4MMgC] 41111 solution (pH 8,0) K dissolved (
blood cells and blood cells).

田χ合成基質Boo−Leu−Gly−ムrg−pHム
−HC’iを1.6MI/dとなるように&’射M、m
1ir水に溶解した。
The synthetic substrate Boo-Leu-Gly-mrg-pH-HC'i was injected at 1.6 MI/d.
Dissolved in 1ir water.

ハ)、実施例λで調製した各種濃度のOMF51@波0
.05aF、血球紬出饋含有液0.025wtおよび合
成基質溶液0.025dから表る反応液0゜1−を滅菌
試験管中、37℃で30分間反応させえ。
C), OMF51 of various concentrations prepared in Example λ @ wave 0
.. A reaction solution of 0.05aF, 0.025wt of a blood cell extraction solution and 0.025d of a synthetic substrate solution was reacted at 37°C for 30 minutes in a sterile test tube.

二χ夏応後、実施例/と同様に処理してム405を側室
した。
After the second summer, Mu405 was concubined and treated in the same manner as in Example.

表3 表3に示すように、CMFgは米国産カブ(ガニOjk
球抽出吻を使用し丸場合にも、日本産カブし丸。
Table 3 As shown in Table 3, CMFg is
If you use a ball extraction proboscis to make a round, you can also use a Japanese turnip round.

賓施例腐 イχ抗鳳瘍性複舎多糖りVスチン(呉羽化学工業株式余
社製)(癌と化学療法1.251 (1974) )を
2岬/dとなるようKO,111&O!Iに溶解し、−
表装置しえOち実施例1と同様に希釈して種々の濃度O
りVスチン溶液を調製しえ。
KO, 111&O! Dissolved in I, -
The table device was diluted in the same manner as in Example 1 to obtain various concentrations.
Prepare a V-stin solution.

イχ Rhodotolula glutlnlg I
 P 01 125株(I?Latitute For
 Periaentatlon 0saka Li5t
 ofCulture81978 jixth 511
tlon K掲載)を200sr賽三角フラスコ内のグ
ルスース3.O%。
Iχ Rhodotolula glutlnlg I
P 01 125 shares (I? Latitude For
Periaentatlon 0saka Li5t
ofCulture81978 jixth 511
tlon K) in a 200sr Erlenmeyer flask.3. O%.

酵母エキXQ、 3X e (NH4)5HHPO4G
−1sx、 KH2PO40,1% 、 Mg804−
7120 0.05%、pH6,8G液体培地50mg
K接種して、2g℃で3日間回転捩盪培養しえ、この培
養液をさらに上記液体培地250wt0入つ九10本0
11春三角フヲススに5dずつ移し、25℃で4日間回
転擾盪培養して培養液2.51を得た。
Yeast extract XQ, 3X e (NH4)5HHPO4G
-1sx, KH2PO40.1%, Mg804-
7120 0.05%, pH 6,8G liquid medium 50mg
K inoculated and cultured with rotary shaking at 2g℃ for 3 days.
11 Spring, 5 d each was transferred to a triangular glass tube and cultured with rotational shaking at 25° C. for 4 days to obtain a culture solution 2.51.

ワ)、培養液を遠心し、得られ丸遠心上清2.47jに
20.3gの酢酸ナトリウムを加えたOち2.471の
エタノールを添加した。得られえ沈澱物を遠心によシ集
め、500m0水に溶解して、4.1gの酢酸ナトリウ
ムを加ええのち811mのエタノールを添加した。得ら
′tL九沈酸沈澱物いてこの操作を2回く〉返し、沈澱
物をエタノ−声で洗浄したのち乾燥して2.4gO多糖
1125を得九。多糖11250糖含量はフェノール−
硫酸法によpssx゛と算出された。
iv) The culture solution was centrifuged, and 20.3 g of sodium acetate was added to 2.47 g of the resulting centrifuged supernatant, followed by 2.47 g of ethanol. The resulting precipitate was collected by centrifugation, dissolved in 500ml of water, and 4.1g of sodium acetate was added followed by 811ml of ethanol. This procedure was repeated twice with the obtained precipitate, and the precipitate was washed with ethanol and dried to obtain 2.4 g of polysaccharide 1125. Polysaccharide 11250 sugar content is phenol-
pssx was calculated by the sulfuric acid method.

ハχ多糖1125紘実施例io方法によ〉測定しえ曽果
、表7に示すように強い抗腫瘍活性を持つことがわかり
え。
The polysaccharide 1125 was measured using the method of Example 1 and was found to have strong antitumor activity as shown in Table 7.

表7 鑵112s1G  ip  5  Li1 85 27
5対1[101α39   0,40 ◆糠11!5ill液を用−1賓施例1と同様にしてカ
ブ側ガニ血球抽出物中omvii*素前駆体活性化簡を
測定し丸。
Table 7 112s1G ip 5 Li1 85 27
5:1 [101α39 0,40 ◆Bran 11! Using 5ill liquid, the amount of activated omvii* element precursor in turnip side crab hemocyte extract was measured in the same manner as in Example 1.

表8 表$に示すように、多糖112Sは1G  シよび10
−” q/dで強い凝固酵素前駆体活性化能を示し九。
Table 8 As shown in Table $, polysaccharide 112S is 1G and 10
-” q/d shows strong coagulation enzyme precursor activation ability.9.

参考例1 抗腫瘍作用が知られていないア(p−ス、デキストフン
、フミナリンおよびイメリンなどOS薄液について、実
施例1と同様O方法でリムμステス)を行なったが、1
0−7〜10−’ fll/d Oいずれの濃度におい
て4陽性を示さなかった。
Reference Example 1 A thin OS solution such as p-su, dextofun, huminarin, and imelin, which is not known to have an antitumor effect, was tested using the O method in the same manner as in Example 1.
No 4 positivity was shown at any concentration between 0-7 and 10-' fll/dO.

Claims (1)

【特許請求の範囲】[Claims] カブFガニの血球抽出物に*買上エンドトキVンを含t
ない多糖希薄液を接触させ、ツムWステスト陽性を示す
多糖を選択することを特徴とする抗腫瘍作用を有する多
糖のスクリーニング法。
Turnip F crab blood cell extract contains *purchased endotoxin V.
1. A method for screening polysaccharides having antitumor activity, which comprises contacting a diluted polysaccharide solution with a polysaccharide containing a polysaccharide, and selecting polysaccharides that show a positive Tsum W test.
JP15264581A 1981-09-26 1981-09-26 Screening of antitumor polysaccharide Granted JPS5853760A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP15264581A JPS5853760A (en) 1981-09-26 1981-09-26 Screening of antitumor polysaccharide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15264581A JPS5853760A (en) 1981-09-26 1981-09-26 Screening of antitumor polysaccharide

Publications (2)

Publication Number Publication Date
JPS5853760A true JPS5853760A (en) 1983-03-30
JPH0151785B2 JPH0151785B2 (en) 1989-11-06

Family

ID=15544932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP15264581A Granted JPS5853760A (en) 1981-09-26 1981-09-26 Screening of antitumor polysaccharide

Country Status (1)

Country Link
JP (1) JPS5853760A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02141666A (en) * 1988-11-24 1990-05-31 Wako Pure Chem Ind Ltd Deactivation of endotoxin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS=1981 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02141666A (en) * 1988-11-24 1990-05-31 Wako Pure Chem Ind Ltd Deactivation of endotoxin

Also Published As

Publication number Publication date
JPH0151785B2 (en) 1989-11-06

Similar Documents

Publication Publication Date Title
Meyer Mucoids and glycoproteins
Keller et al. Structural differences between the isoenzymes of human parotid α-amylase
So et al. Protein-Carbohydrate Interaction: IV. APPLICATION OF THE QUANTITATIVE PRECIPITIN METHOD TO POLYSACCHARIDE-CONCANAVALIN A INTERACTION
Alastair et al. Carcinoembryonic antigen and blood group substances
Roberts Isolation and characterisation of glycoproteins from sputum
Brogan The carbohydrate complexes of bronchial secretion
Carter The carbonic anhydrase in the rumen epithelial tissue of the ox
Agrawal et al. Protein-carbohydrate interaction. XVIII. Preparation and properties of acetylated concanavalin A, the hemagglutinin of the jack bean
Tu et al. Isolation and characterization of the toxic component of Enhydrina schistosa (common sea snake) venom
Kabat et al. IMMUNOCHEMICAL STUDIES ON BLOOD GROUPS: II. Properties of the Blood Group A Substance from Pools of Hoo Stomachs and of Specific Precipitates Composed of" A" Substance and Homologous Human Antibody
Heidelberger et al. Serological reactivity of synthetic polyglucoses
Tanford THE ACID DENATURATION OF FERRIHEMOGLOBIN1
JPS5853760A (en) Screening of antitumor polysaccharide
CN107091925A (en) A kind of antibody chip and kit for detecting periodontitis GAP-associated protein GAP
Stiefel et al. Comparison of human pancreatic and parotid amylase activities on different substrates
EP3018147B1 (en) Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof
Saeed et al. Food protein: food colour interactions and its application in rapid protein assay.
US3753864A (en) Precipitating solution for amylase assay
Johansen Physiochemical investigations on two unusual sialic acid-rich mucoids from the intestinal tract of patients with fibrocystic disease of the pancreas
JPS5885899A (en) Amylase inhibitor and its preparation
NOMURA et al. STUDIES ON AMYLASE FORMATION BY BACILLUS SUBTILIS V. IMMUNOCHEMICAL STUDIES OF AMYLASE PRODUCED BY BACILLUS SUBTILIS
Chiao et al. Interaction of modified haptoglobin with hemoglobin
JP2854872B2 (en) Insoluble carrier with antimicrobial peptide derived from horseshoe crab blood cell membrane as ligand
CN109323996A (en) A kind of fungal detection kit
Whittingham et al. Crystal structures of the GH18 domain of the bifunctional peroxiredoxin–chitinase CotE from Clostridium difficile